

Antiviral Chemistry & Chemotherapy
Guidelines for preparation of manuscripts

EDITORIAL POLICY	3
Ethics	3
SUBMISSION CATEGORIES.....	4
Original article.....	4
Review	4
Pointer	4
Short communication	4
Workshop report	4
Letter	4
MANUSCRIPT FORMAT	5
Title	5
Authors	5
Corresponding author details.....	5
Running head.....	5
Structured abstract	6
Main text	6
Introduction	6
Methods (Chemistry and Virology).....	6
Results	6
Discussion.....	6
Acknowledgements.....	6
Disclosure statement.....	6
References	7
Standard journal article.....	7
More than six authors	7
Translated journal title	7
Book	7
Chapter in a book.....	7
Abstract.....	7
Website	7
Prescribing information	7

Patents.....	8
Display items	8
Tables	8
Figures	8
Supplementary material	9
GENERAL POINTS ON MANUSCRIPT PREPARATION	9
Drug names	9
Spelling	9
Units of measurement.....	9
Abbreviations and symbols.....	9
IMMEDIATE PUBLICATION.....	9
PROOFS.....	9
COPYRIGHT ASSIGNMENT	9
OFFPRINTS	10
EDITORIAL OFFICE	10

Antiviral Chemistry & Chemotherapy Guidelines for preparation of manuscripts

EDITORIAL POLICY

Antiviral Chemistry & Chemotherapy publishes the results of original research on all aspects of antiviral compounds and chemotherapy. Manuscripts concerned with the biochemistry, mode of action, pharmacology, synthesis and virology of antiviral agents will be welcomed, as will animal model studies. Chemical papers may show negative antiviral effects providing the virological rationale for the synthesis of the compounds is clearly stated and sound biological/virological methodology is described. A reasoned antiviral rationale, rather than the novelty of the chemistry, will be regarded as of major importance.

Manuscripts submitted to *Antiviral Chemistry & Chemotherapy* are considered for publication on the understanding that the work contained therein has not been submitted simultaneously to another journal. Copies of related manuscripts submitted elsewhere or in press should accompany the submitted manuscript.

All submissions must be accompanied by a covering letter (a [letter template](#) is available on the online submission website), signed by all the authors (or the corresponding author on behalf of all others) stating that all authors have contributed to the paper and are familiar with the contents of the final draft, and that all authors meet the criteria for authorship as established by the [International Committee of Medical Journal Editors](#). The letter, and manuscript, should also state whether any author has any conflicts of interests (see 'Disclosure statement' section for our guidelines on what constitutes a conflict of interest). Sources of funding, any influence the funding source may have had on the analysis and reporting of the results, and any related interest must be declared in the Acknowledgements section. All disclosures and declarations must also be summarized in the manuscript itself. Illustrations and other material obtained from other sources must be acknowledged and it is the author's responsibility to obtain permission for reproduction from the publisher. Copies of permission letters/e-mails must be provided to the Editorial Office upon request for all accepted articles.

All manuscripts should be submitted via the [online ScholarOne site](#). Manuscripts will not be accepted via e-mail or post.

Papers will be peer reviewed and assessed statistically before acceptance. Priority and time of publication of accepted material will be decided by the Editor. The Editor retains the right to shorten material accepted for publication. This can include subediting the text for style. The Editors endorse the [guidelines on good publication practice](#) from the Committee on Publication Ethics (COPE) and [GPP2](#).

Ethics

Papers based on clinical investigation must conform to ethical standards as set out in the Declaration of Helsinki. Reports describing data obtained from experiments performed in animals must clearly indicate that humane standards were adhered to.

For experiments on isolated tissues the paper must indicate precisely how the donor tissue was obtained. The NIH *Guide for the Care and Use of Laboratory Animals* (National Institutes of Health Publications) gives guidelines for the acquisition and care of animals. The UK Home Office also provides [guidelines on the use of animals for research](#).

SUBMISSION CATEGORIES

Original article

Normal limits: ≤4,000 words, ≤50 references, ≤5 display items

An abstract that includes the sections background, methods, results and conclusions should be provided. The maximum word count for the abstract is 250 words. A disclosure statement is required. Please see [manuscript format](#) below.

Review

Reviews are usually commissioned but unsolicited reviews are welcomed. Articles will be assessed in-house and those considered suitable will be peer reviewed before an editorial decision is made. Reviews may be highly focused or cover a broad area, but the scope of the review should be briefly stated in the abstract and fully stated in the introduction. The word count will depend on the breadth of the topic, but the abstract should be no longer than 100 words. References selected for publication in the journal should be chosen for their importance, ease of access, and for the 'further reading' opportunities they provide. A disclosure statement is also required.

Pointer

Normal limit: ≤1,500 words

Pointers are scholarly articles of contemporary interest. The aim of a Pointer is to highlight a new research direction normally arising from one's own research or series of publications; to comment on a topical issue or situation; or to briefly review an article, expanding on the underlying themes and commenting on its significance in changing future research or therapy. As such articles point to the future, this will involve, necessarily, the author or authors' personal opinion. Most are commissioned, although unsolicited Pointers are welcomed. Articles will be assessed in-house and those considered suitable will be peer reviewed before an editorial decision is made. References to all the important source documents should be included, and should be chosen for their importance, ease of access, and for the 'further reading' opportunities they provide. A disclosure statement and abstract (<100 words) are also required. For advice on length please contact the [Editorial Office](#).

Short communication

Normal limits: ≤1,500 words, ≤20 references, ≤3 display items

Original research findings that do not require a full paper, but are completed studies, may be submitted as a short communication. All short communications should contain an introduction, methods, results and discussion section and should have a structured abstract (background, methods, results and conclusions; maximum 250 words). A disclosure statement is also required.

Workshop report

Normal limits: ≤1,500 words, ≤20 references

The Journal encourages submissions on written reports from relevant and recent workshops and conferences. An abstract (<100 words) and disclosure statement are required.

Letter

Normal limits: ≤1,000 words, ≤15 references, ≤2 display items

Letters are articles that address issues or exchange views on topics arising from published articles in *Antiviral Chemistry & Chemotherapy*. A disclosure statement is required.

MANUSCRIPT FORMAT

Manuscripts should be prepared in accordance with '[Uniform Requirements for Manuscripts Submitted to Biomedical Journals](#)' (International Committee of Medical Journal Editors).

All manuscripts should be submitted using editable files (Word in .doc format is preferable for text, .jpg and .pdf for figures); manuscripts will be converted to PDFs for peer-review.

The key features of manuscripts are listed and described below:

- [Title](#)
- [Authors](#)
- [Corresponding author details](#)
- [Running head](#)
- [Structured abstract](#) (original articles and short communications)
- [Introduction](#)
- [Materials and methods](#) (these can be divided into *Chemistry* and *Virology* if appropriate)
- [Results](#)
- [Discussion](#)
- [Acknowledgements](#)
- [Disclosure statement](#)
- [References](#)
- [Display items](#) (optional)
- [Supplementary material](#) (optional)

Title

Use of abbreviations should be avoided in the title and it should not exceed three typeset lines (~150 characters, including spaces).

Authors

Forenames and brief addresses should be included. If an author's current affiliation address differs from the one at which the research was conducted this may also be indicated. Authors (including members of study groups, working group and the like) included in the byline must satisfy the criteria of authorship given by the [International Committee of Medical Journal Editors](#). All individuals who qualify for authorship must be included.

A multicentre group can be credited with sole authorship; however, the group must identify and include in their manuscript a corresponding author on the title page and the principle investigators who accept direct responsibility for the manuscript in a separate section entitled 'Writing group' before the references. These principle investigators should fully meet the criteria for authorship defined by the [International Committee of Medical Journal Editors](#) and be willing to complete relevant journal-specific forms on behalf of the group. A full membership list will be published online as an additional file.

Corresponding author details

Only the corresponding author's e-mail address should be supplied. Unless instructed otherwise, the Editorial Office will send page proofs of the article to this e-mail address.

Running head

A running head of up to 75 characters should be supplied. This will appear at the top of each right-hand page.

Structured abstract (original articles and short communications)

The headings background, methods, results, conclusions should be used. The abstract must not exceed 250 words. References, compound numbers and display item citations must not appear in the abstract, and the abstract must be clear and comprehensible in its own right.

Main text**Introduction**

Background and relevance to current study.

Materials and methods (these can be divided into Chemistry and Virology if appropriate)

The supplier (with brief address including city, state and country) must be given for all laboratory equipment and materials.

- **Chemistry**

Procedures used for the synthesis of novel compounds (where there is a specific antiviral rationale) together with spectral and analytical data establishing their structure and purity should be reported briefly in the *Materials and methods* and under the subheading *Chemistry* if appropriate. Authors should be concise and whenever possible use a format that describes general reaction conditions (only once), tabulating experimental data to afford effective presentation and economical use of space. The title of an experiment should include the chemical name of the product (preferably [IUPAC](#) nomenclature) and a compound number. Compound numbers should be presented as a bold number, for example **1**. Chemical compounds should be drawn in accordance with the 1996 American Chemical Society (ACS) settings. Additional analytical data required for refereeing may be deposited with the Editors as 'supplementary data'. Data from X-ray diffraction studies for organic compounds or metal-organic compounds should be deposited with the Cambridge Crystallographic Data Centre (CCDC). Full details on deposition can be found at: <http://www.ccdc.cam.ac.uk/products/csd/deposit/>

- **Virology**

Quantitative biological data will be required on all 'target' compounds and the methods may be described under the subheading *Virology* if appropriate.

Results

Presentation of data.

Discussion

Interpretation of results in context of other published data.

Acknowledgements

Acknowledgements should be made to those, not including the authors, who have made a substantial contribution to the study. Authors are responsible for obtaining written permission from people acknowledged by name in case readers infer their endorsement of data and conclusions.

Details of sources of funding, editorial support and previous presentation of should be placed in this section, when appropriate. A summary of the role of each author on a collaborative paper may also be included.

Disclosure statement

All conflicts of interest relevant to the article should be disclosed in this section. If there are no conflicts of interest, a sentence to this effect should be included. [See ICMJE guidelines](#) for more information.

References

The accuracy of references is essential and this remains the responsibility of the author. As formatting information (italics, special characters and subscript and superscript text) is often lost on websites such as PubMed or in referencing databases such as Review Manager and EndNote, the original versions should be consulted. References must be cited numerically by order of appearance in the text and listed in the bibliography. References should be cited in square brackets, for example, [3] or [1,3–5]. The manuscript Reference section must present full references in the formats given below.

In the full list of references give the names and initials of all authors. If there are more than six, cite only the first three, followed by *et al.* The authors' names are followed by the title of the article, the title of the journal (italics) abbreviated according to the style of [Index Medicus](#), the year of publication; the volume number (in bold) and the first and last page numbers in full followed by a full stop. Titles of books should be followed by the town and country of publication, the publisher, the year and inclusive page numbers. See the following examples:

Standard journal article

1. Bar S, Alizon M. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. *J Virol* 2004; **78**: 811–820.

More than six authors

2. Hirsch MS, Brun-Vézinet F, Clotet B, *et al.* Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. *Clin Infect Dis* 2003; **37**:113–128.

Translated journal title

3. Schäfer W. [Comparative sero-immunological investigations on the viruses of influenza and classical fowl plague]. *Zeitschrift für Naturforschung* 1955; **10b**:81–91. German.

Book

4. Glantz SA. *Primer of biostatistics*. 3rd ed. New York: McGraw–Hill 1997.

Chapter or selected pages in a book

5. Varmus HE, Swanstrom R. Replication of retroviruses. In Weiss R, Teich N, Varmus H, Coffin J (Editors). *RNA tumor viruses*. Vol. 1. New York: Cold Spring Harbor Laboratory Press 1994; pp. 369–512.

Abstract

6. Ranade K, Parker R, Ploughman L, *et al.* A single nucleotide polymorphism in the resistin gene is associated with adverse metabolic changes on HAART: an exploratory pharmacogenetic association study of A5005s, the metabolic sub-study of ACTG 384. *13th Conference on Retroviruses and Opportunistic Infections*. 5–8 February 2006, Denver, CO, USA. Abstract 763.

Website

7. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 10 October 2006. Accessed 3 August 2007.) Available from <http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf>

Prescribing information

8. Viread (tenofovir disoproxil fumarate). *Package insert* 2005. Gilead Sciences, Foster City, CA, USA.

Patents

9. Hurst DN, Jones PS, Parkes KEB, Parratt MJ, Wilson FX, inventors; Hoffmann-La Roche Inc., assignee. Inhibitors of HPV E1 helicase enzyme. United State patent US 6703387. 2004 March 9.

Display items

References to figures and tables should be made in order of appearance in the text and should be in Arabic numerals in parentheses, e.g. (Figure 2). Any abbreviation used in a figure or table must be defined in the footnote. Units for figure axis labels and table headings should be stated after a comma, for example 'Time, years' or 'HCV RNA, log₁₀ copies/ml'. Place explanatory matter in footnotes, not in the heading or within the table or figure. The footnote symbols used in the journal are ^a, ^b, ^c, ^d, ^e, ^f and so on, and appear in order from top to bottom and left to right.

If a figure or table has been published before, in total or in part, the original source must be acknowledged and written permission from the copyright holder for both print and electronic formats should be submitted with the material. It is the responsibility of the author to obtain this permission, and failure to do so may delay publication. Permission is required regardless of authorship or publisher, except for documents in the public domain.

Tables

Create tables using the table editor of a Word processing package. Do not embed tables as images in the manuscript file or upload tables in image or PDF formats. Each piece of data needs to be contained in its own cell in the table. Vertical rules should not be used. Avoid creating tables using spaces or tabs. Do not align cells with hard returns or extra spaces. Furthermore, no cell should contain a hard return or tab. Although individual empty cells are acceptable, be sure there are no empty columns. Tables should not be split into separate sections and should not exceed one typeset page in size. Data within tables should be left aligned. Shading is not allowed in tables as they cannot be represented in xml for online publication.

Each table should be assigned an Arabic numeral (eg Table 1, Table 2) and should not be split in separate parts (eg Table 1A, Table 1B etc). Each should also have a brief title. Identify all statistical measures, along with all units.

Please note, accepted manuscripts not following these table guidelines must be retyped during the editing process, which may result in delays and opportunities for error.

Figures

Figures may be reduced, cropped or omitted at the discretion of the editor. Colour illustrations are acceptable and will incur no extra cost. All chemical compounds should be drawn in accordance with the American Chemical Society's (ACS) 1996 settings. Chemical schemes should be supplied as standard figures and be called figures. Where a figure has several parts these should be labelled with upper-case letters. No lettering should be placed directly over images. Amino-acid sequences should be given in Courier or a similar monospaced font.

For ease of review, clear and complete figures should be submitted in .jpg or .pdf.

Should the article be accepted for publication, the authors should be ready to supply print-quality images in cases of electron micrographs, images of blots and gels, computer-generated protein structures and the like. This will ideally be in .eps format for computer-generated images (all programs have the facility to print to an .eps file) or .tif format for photographic images. Images intended to be printed across the width of one column should be a minimum of 900 pixels (5 cm wide at 300 dpi) in width. Those intended to occupy two columns should be a minimum of 1,300 pixels (11 cm at 300 dpi) in width. It is also worth remembering that RGB colour profile figures will necessarily be converted to CMYK for printing – therefore if possible authors should supply figures as CMYK, to ensure that the alteration in colour is satisfactory.

Graphs, schemes and simple diagrams will be redrawn by in-house illustrators so the initially submitted images will usually be sufficient.

Supplementary material

Supplementary data can be published as additional files as part of the online journal. It should be referred to within the text. Lists of members of study groups and similar can also be incorporated into the supplementary material. Supplementary material will be reproduced as submitted and will not be subedited or styled by the Editorial Office.

GENERAL POINTS ON MANUSCRIPT PREPARATION

Drug names

International non-proprietary names (INN or USAN) for drugs should be used throughout the text.

Spelling

Spelling should follow the Oxford English Dictionary.

Units of measurement

SI units of measurement should be used wherever applicable. Temperatures should be given in degrees Celsius. Metrics units should be used throughout (for example, 5 kg).

Abbreviations and symbols

The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement. Abbreviations that have been defined in the abstract must be defined again at first mention in the main text. Abbreviations should only be used when helpful to the reader, as an improvement in clarity. As a guideline, use abbreviations for terms appearing three or more times in the article. Use only standard abbreviations. Avoid abbreviations in the title and abstract. All abbreviations must be redefined in each table and figure in which they are used.

IMMEDIATE PUBLICATION

Accepted articles will be published immediately online after acceptance before being copy-edited. For this reason, please ensure title, author names, affiliations, corresponding author e-mails and abstract are correct at the time of submission.

PROOFS

Copy-edited page proofs of articles will be sent to the corresponding author shortly before publication and these should be corrected and returned within 2 days. For this reason please ensure that the e-mail address supplied is checked regularly. Only corrections and essential changes should be made and the cost of additional changes will be charged to the authors. However, in some cases information that has become available since acceptance of the manuscript may be included as an addendum in proof. This is at the discretion of the Editors. The editors reserve the right to make minor modifications to the manuscripts. Material changes will be submitted to the authors for approval at the proof stage.

COPYRIGHT ASSIGNMENT

To facilitate effective dissemination of the article, copyright must be transferred to the publisher before publication. Copyright assignment forms are available from the Editorial Office, but will usually be supplied upon acceptance.

OFFPRINTS

The corresponding author of each published article may obtain a PDF of the final version of the article from the Editorial Office. Authors can purchase offprints at reduced rates and a form will be sent along with the page proofs.

EDITORIAL OFFICE

International Medical Press
Admiral House
76–78 Old Street
EC1V 9AZ
UK

Tel: +44 (0) 20 7398 0700
Fax: +44 (0) 20 7398 0701
E-mail: info@intmedpress.com
<http://www.intmedpress.com>